Get the Stockscreener App
0.3248
0.93%
0.003
After Hours:
.33
0.0052
+1.60%
Marinus Pharmaceuticals Inc stock is traded at $0.3248, with a volume of 589.47K.
It is up +0.93% in the last 24 hours and down -19.82% over the past month.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
See More
Previous Close:
$0.3218
Open:
$0.3218
24h Volume:
589.47K
Relative Volume:
0.24
Market Cap:
$17.76M
Revenue:
$30.99M
Net Income/Loss:
$-141.41M
P/E Ratio:
-2.1653
EPS:
-0.15
Net Cash Flow:
$-118.12M
1W Performance:
+5.11%
1M Performance:
-19.82%
6M Performance:
-76.46%
1Y Performance:
-94.84%
1-Day Range:
$0.3108
$0.325
1-Week Range:
$0.302
$0.34
52-Week Range:
$0.2603
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Name
Marinus Pharmaceuticals Inc
Sector
Industry
Phone
484-801-4670
Address
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Compare MRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.3248 | 17.76M | 30.99M | -141.41M | -118.12M | -0.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-16-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-15-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-20-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-30-20 | Initiated | Truist | Buy |
| Jul-01-20 | Initiated | Cowen | Outperform |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-09-20 | Initiated | Craig Hallum | Buy |
| Dec-20-19 | Initiated | Oppenheimer | Outperform |
| Mar-05-19 | Resumed | Jefferies | Buy |
| Feb-27-19 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-19 | Initiated | Leerink Partners | Outperform |
| Jul-02-18 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-20-18 | Initiated | Mizuho | Buy |
| Feb-15-18 | Initiated | H.C. Wainwright | Buy |
| Dec-14-17 | Initiated | Laidlaw | Buy |
| Aug-10-16 | Reiterated | Jefferies | Buy |
| Jun-14-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-08-16 | Reiterated | Stifel | Buy |
| Dec-17-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-17-15 | Initiated | Jefferies | Buy |
| Oct-30-15 | Reiterated | Oppenheimer | Outperform |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
View All
Marinus Pharmaceuticals Inc Stock (MRNS) Latest News
Marinus Pharmaceuticals (LTS:0JYL) COGS-to-Revenue : 0.08 (As of Sep. 2024) - GuruFocus.com
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investor - GuruFocus.com
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
CDKL5 Deficiency Disorder Market Revenue to Expand - openPR
Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace
Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments - MSN
MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com
Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance
Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks
Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
Marinus downgraded after setback to late-stage trial - MSN
Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN
TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN
Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal
Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN
Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks
Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha
HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices
Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues
JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus halts ganaxolone development after trial setback - Investing.com India
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India
Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK
Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia
Truist cuts Marinus Pharma to hold, drops price target - Investing.com
Marinus Pharmaceuticals Inc Stock (MRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Marinus Pharmaceuticals Inc Stock (MRNS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Aug 05 '24 |
Sale |
1.14 |
3,820 |
4,355 |
67,406 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Aug 05 '24 |
Sale |
1.13 |
3,621 |
4,092 |
60,263 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Aug 05 '24 |
Sale |
1.13 |
4,828 |
5,456 |
72,725 |
| Braunstein Scott | CHAIRMAN AND CEO |
Aug 05 '24 |
Sale |
1.13 |
12,145 |
13,724 |
298,667 |
| Braunstein Scott | CHAIRMAN AND CEO |
Mar 27 '24 |
Option Exercise |
4.28 |
50,000 |
214,000 |
273,512 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Feb 20 '24 |
Sale |
9.56 |
2,153 |
20,583 |
60,308 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Feb 20 '24 |
Sale |
9.57 |
1,894 |
18,126 |
52,966 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Feb 16 '24 |
Sale |
9.98 |
2,814 |
28,084 |
66,635 |
| Pfanstiel Steven | CFO AND COO |
Feb 16 '24 |
Sale |
9.97 |
3,092 |
30,827 |
71,697 |
| Braunstein Scott | CHAIRMAN AND CEO |
Feb 16 '24 |
Sale |
9.94 |
11,850 |
117,789 |
223,512 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):